videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Embla Medical

Embla Medical will release its Q3 2025 interim report on October 21, 2025. On the same day at 10:30 CEST, the company’s management will present the results and answer questions during a live online event.

You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit questions for the event. Embla Medical will release its Q3 2025 interim report on October 21, 2025. On the same day at 10:30 CEST, the company&#x2019;s management will present the results and answer questions during a live online event. Embla Medical&#x2019;s Q2 2025 results showed an increase in organic growth to 5%, up from 4% in the first quarter. Growth, as in Q1, was driven by the Prosthetics &amp; Neuro Orthotics business segment and, regionally, by the APAC and EMEA markets. The Patient Care segment and the US market continued to lag, although there was a slight improvement compared to Q1 2025. EBITDA margins for the first half of the year improved by 1 percentage point compared to the same period last year, reaching 20%. Based on the first half-year results, the company narrowed its 2025 outlook for organic growth to 5&#x2013;6% (previously 5&#x2013;8%) but reaffirmed its expectation of an EBITDA margin of 20&#x2013;21%. With guidance indicating a pickup in the second half of the year, the focus around the Q3 results will be whether the results confirm these expectations for a stronger H2 2025. In addition to the financial results, investor attention may also focus on the momentum in the newly launched Navii and Icon bionic knees, and the fact that a main competitor has announced its intention to IPO in the latter part of 2025. Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. The company enhances people&#x2019;s mobility through the development and delivery of Prosthetics &amp; Neuro Orthotics, Bracing &amp; Supports, and Patient Care. Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 16.32, 24-09-2025.

Embla Medical – Presentation of Q3 2025 Interim Report

Viimeisimmät videot